Yes-associated protein regulates the hepatic response after bile duct ligation

Abstract

Human chronic cholestatic liver diseases are characterized by cholangiocyte proliferation, hepatocyte injury, and fibrosis. Yes-associated protein (YAP), the effector of the Hippo tumor-suppressor pathway, has been shown to play a critical role in promoting cholangiocyte and hepatocyte proliferation and survival during embryonic liver development and hepatocellular carcinogenesis. Therefore, the aim of this study was to examine whether YAP participates in the regenerative response after cholestatic injury. First, we examined human liver tissue from patients with chronic cholestasis. We found more-active nuclear YAP in the bile ductular reactions of primary sclerosing cholangitis and primary biliary cirrhosis patient liver samples. Next, we used the murine bile duct ligation (BDL) model to induce cholestatic liver injury. We found significant changes in YAP activity after BDL in wild-type mice. The function of YAP in the hepatic response after BDL was further evaluated with liver-specific Yap conditional deletion in mice. Ablating Yap in the mouse liver not only compromised bile duct proliferation, but also enhanced hepatocyte necrosis and suppressed hepatocyte proliferation after BDL. Furthermore, primary hepatocytes and cholangiocytes isolated from Yap - deficient livers showed reduced proliferation in response to epidermal growth factor in vitro . Finally, we demonstrated that YAP likely mediates its biological effects through the modulation of Survivin expression. Conclusion : Our data suggest that YAP promotes cholangiocyte and hepatocyte proliferation and prevents parenchymal damage after cholestatic injury in mice and thus may mediate the response to cholestasis-induced human liver disease.

Shown for reading. Its publisher allows quoting it, not republishing it.

References 55

1. 1.

   Lazaridis KN, Strazzabosco M, LaRusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology. 2004;127:1565-1577.

   Not in our library10.1053/j.gastro.2004.08.006

2. 2.

   Alvaro D, Mancino MG. New insights on the molecular and cell biology of human cholangiopathies. Mol Aspects Med. 2008;29:50-57.

   Not in our library10.1016/j.mam.2007.09.007

3. 3.

   Schmucker DL, Ohta M, Kanai S, Sato Y, Kitani K. Hepatic injury induced by bile salts: correlation between biochemical and morphological events. HEPATOLOGY. 1990;12:1216-1221.

   Not in our library10.1002/hep.1840120523

4. 4.

   Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115:209-218.

   Not in our library10.1172/jci24282

5. 5.

   Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, Stanger BZ, et al. Intrahepatic bile ducts develop according to a new mode of tubulogenesis regulated by the transcription factor SOX9. Gastroenterology. 2009;136:2325-2333.

   Not in our library10.1053/j.gastro.2009.02.051

6. 6.

   Lozier J, McCright B, Gridley T. Notch signaling regulates bile duct morphogenesis in mice. PLoS ONE. 2008;3:e1851.

   Not in our library10.1371/journal.pone.0001851

7. 7.

   Omenetti A, Yang L, Li YX, McCall SJ, Jung Y, Sicklick JK, et al. Hedgehog-mediated mesenchymal-epithelial interactions modulate hepatic response to bile duct ligation. Lab Invest. 2007;87:499-514.

   Not in our library10.1038/labinvest.3700537

8. 8.

   Que FG, Phan VA, Phan VH, LaRusso NF, Gores GJ. GUDC inhibits cytochrome c release from human cholangiocyte mitochondria. J Surg Res. 1999;83:100-105.

   Not in our library10.1006/jsre.1999.5574

9. 9.

   Sackett SD, Gao Y, Shin S, Esterson YB, Tsingalia A, Hurtt RS, et al. Foxl1 promotes liver repair following cholestatic injury in mice. Lab Invest. 2009;89:1387-1396.

   Not in our library10.1038/labinvest.2009.103

10. 10.

    Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, et al. Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem. 2001;276:15164-15173.

    Not in our library10.1074/jbc.m010484200

11. 11.

    Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J. 1999;18:2551-2562.

    Not in our library10.1093/emboj/18.9.2551

12. 12.

    Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev. 2001;15:1229-1241.

    Not in our library10.1101/gad.888601

13. 13.

    Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120-1133.

    Not in our library10.1016/j.cell.2007.07.019

14. 14.

    Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 2010;19:491-505.

    Not in our library10.1016/j.devcel.2010.09.011

15. 15.

    Zhao B, Wei X, Li W, Udan RS, Yang Q, Kim J, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747-2761.

    Not in our library10.1101/gad.1602907

16. 16.

    Zhang J, Ji JY, Yu M, Overholtzer M, Smolen GA, Wang R, et al. YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol. 2009;11:1444-1450.

    Not in our library10.1038/ncb1993

17. 17.

    Camargo FD, Gokhale S, Johnnidis JB, Fu D, Bell GW, Jaenisch R, et al. YAP1 increases organ size and expands undifferentiated progenitor cells. Curr Biol. 2007;17:2054-2060.

    Not in our library10.1016/j.cub.2007.10.039

18. 18.

    Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, et al. The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:8248-8253.

    Not in our library10.1073/pnas.0912203107

19. 19.

    Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, et al. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A. 2010;107:1437-1442.

    Not in our library10.1073/pnas.0911427107

20. 20.

    Song H, Mak KK, Topol L, Yun K, Hu J, Garrett L, et al. Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. Proc Natl Acad Sci U S A. 2010;107:1431-1436.

    Not in our library10.1073/pnas.0911409107

21. 21.

    Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, et al. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell. 2010;19:27-38.

    Not in our library10.1016/j.devcel.2010.06.015

22. 22.

    Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell. 2009;16:425-438.

    Not in our library10.1016/j.ccr.2009.09.026

23. 23.

    Avruch J, Zhou D, Fitamant J, Bardeesy N. Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br J Cancer. 2011;104:24-32.

    Not in our library10.1038/sj.bjc.6606011

24. 24.

    Baldwin C, Garnis C, Zhang L, Rosin MP, Lam WL. Multiple microalterations detected at high frequency in oral cancer. Cancer Res. 2005;65:7561-7567.

    Not in our library10.1158/0008-5472.can-05-1513

25. 25.

    Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A. 2006;103:12405-12410.

    Not in our library10.1073/pnas.0605579103

26. 26.

    Snijders AM, Schmidt BL, Fridlyand J, Dekker N, Pinkel D, Jordan RC, et al. Rare amplicons implicate frequent deregulation of cell fate specification pathways in oral squamous cell carcinoma. Oncogene. 2005;24:4232-4242.

    Not in our library10.1038/sj.onc.1208601

27. 27.

    Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 2006;125:1253-1267.

    Not in our library10.1016/j.cell.2006.05.030

28. 28.

    Bashyam MD, Bair R, Kim YH, Wang P, Hernandez-Boussard T, Karikari CA, et al. Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia. 2005;7:556-562.

    Not in our library10.1593/neo.04586

29. 29.

    Dai Z, Zhu WG, Morrison CD, Brena RM, Smiraglia DJ, Raval A, et al. A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes. Hum Mol Genet. 2003;12:791-801.

    Not in our library10.1093/hmg/ddg083

30. 30.

    Imoto I, Yang ZQ, Pimkhaokham A, Tsuda H, Shimada Y, Imamura M, et al. Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Res. 2001;61:6629-6634.

    Not in our library

31. 31.

    Fernandez L, Northcott PA, Dalton J, Fraga C, Ellison D, Angers S, et al. YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes Dev. 2009;23:2729-2741.

    Not in our library10.1101/gad.1824509

32. 32.

    Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, et al. Expression of Yes-associated protein in common solid tumors. Hum Pathol. 2008;39:1582-1589.

    Not in our library10.1016/j.humpath.2008.04.012

33. 33.

    Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol. 1978;379:103-112.

    Not in our library10.1007/bf00432479

34. 34.

    Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995;269:1427-1429.

    Not in our library10.1126/science.7660125

35. 35.

    Ding JW, Andersson R, Soltesz V, Willen R, Bengmark S. The role of bile and bile acids in bacterial translocation in obstructive jaundice in rats. Eur Surg Res. 1993;25:11-19.

    Not in our library10.1159/000129252

36. 36.

    Georgiev P, Navarini AA, Eloranta JJ, Lang KS, Kullak-Ublick GA, Nocito A, et al. Cholestasis protects the liver from ischaemic injury and post-ischaemic inflammation in the mouse. Gut. 2007;56:121-128.

    Not in our library10.1136/gut.2006.097170

37. 37.

    Kreamer BL, Staecker JL, Sawada N, Sattler GL, Hsia MT, Pitot HC. Use of a low-speed, iso-density percoll centrifugation method to increase the viability of isolated rat hepatocyte preparations. In Vitro Cell Dev Biol. 1986;22:201-211.

    Not in our library10.1007/bf02623304

38. 38.

    Vroman B, LaRusso NF. Development and characterization of polarized primary cultures of rat intrahepatic bile duct epithelial cells. Lab Invest. 1996;74:303-313.

    Not in our library

39. 39.

    Glaser SS, Onori P, Wise C, Yang F, Marzioni M, Alvaro D, et al. Recent advances in the regulation of cholangiocyte proliferation and function during extrahepatic cholestasis. Dig Liver Dis. 2010;42:245-252.

    Not in our library10.1016/j.dld.2010.01.008

40. 40.

    Georgiev P, Jochum W, Heinrich S, Jang JH, Nocito A, Dahm F, Clavien PA. Characterization of time-related changes after experimental bile duct ligation. Br J Surg. 2008;95:646-656.

    Not in our library10.1002/bjs.6050

Cited by papers we hold 3

• The Hippo pathway in tissue homeostasis and regeneration · 2017
  No notice
• LATS-YAP/TAZ controls lineage specification by regulating TGFβ signaling and Hnf4α expression during liver development · 2016
  No notice
• Two-signal requirement for growth-promoting function of Yap in hepatocytes · 2015
  Not checked

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.